The value proposition of molecular medicine
- PMID: 22376267
- PMCID: PMC5404828
- DOI: 10.1111/j.1752-8062.2011.00386.x
The value proposition of molecular medicine
Similar articles
-
Budget impact and cost-effectiveness: can we afford precision medicine in oncology?Scand J Clin Lab Invest Suppl. 2016;245:S6-S11. doi: 10.1080/00365513.2016.1206437. Epub 2016 Jul 18. Scand J Clin Lab Invest Suppl. 2016. PMID: 27426412
-
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.Ann Oncol. 2019 May 1;30(5):663-665. doi: 10.1093/annonc/mdz119. Ann Oncol. 2019. PMID: 31038154 No abstract available.
-
The impact of genomics on the future of medicine and health.Med J Aust. 2014 Jul 7;201(1):17-20. doi: 10.5694/mja13.10920. Med J Aust. 2014. PMID: 24999876 No abstract available.
-
[Health care expenditures linked to the use of targeted therapies and diagnostic tests for cancer patients].Med Sci (Paris). 2012 Mar;28 Spec No 1:19-23. doi: 10.1051/medsci/2012281s106. Epub 2012 Apr 9. Med Sci (Paris). 2012. PMID: 22494652 Review. French.
-
Challenges in the clinical implementation of precision medicine companion diagnostics.Expert Rev Mol Diagn. 2020 Jun;20(6):593-599. doi: 10.1080/14737159.2020.1757436. Epub 2020 Apr 26. Expert Rev Mol Diagn. 2020. PMID: 32336167 Review.
Cited by
-
Mass Customized Outlook for Regenerative Heart Failure Care.Int J Mol Sci. 2021 Oct 22;22(21):11394. doi: 10.3390/ijms222111394. Int J Mol Sci. 2021. PMID: 34768825 Free PMC article. Review.
References
-
- Honig PK. Comparative effectiveness: the fourth hurdle in drug development and a role for clinical pharmacology. Clin Pharmacol Ther. 2011; 89: 151–156. - PubMed
-
- Terzic A, Waldman SA. Translational medicine: path to personalized and public health. Biomark Med. 2010; 4: 787–790. - PubMed
-
- Waldman SA, Hohl RJ, Kearns GL, Swan SJ, Terzic A. Clinical pharmacology as a foundation for translational science. Clin Pharmacol Ther. 2011; 90: 10–13. - PubMed
-
- Waldman SA, Terzic A. Patient‐centric clinical pharmacology advances the path to personalized medicine. Biomark Med. 2011; 5: 697–700. - PubMed
-
- Nelson TJ, Terzic A. Induced pluripotent stem cells: an emerging theranostics platform. Clin Pharmacol Ther. 2011; 89: 648–650. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources